Combined Anti-CD20/Anti-CD38 Therapy in Posttransplant Focal Segmental Glomerulosclerosis Recurrence: A Retrospective, International, Multicenter Study
Transplantation Direct · 20.01.2026 · 12 (2) · e1908
DOI: 10.1097/txd.0000000000001908 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplantation Direct, online erschienen am 20.01.2026. Verfasst von Paolo Cravedi und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Transplantation Research Center, Icahn School of Medicine at Mount Sinai, New York, NY. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Focal segmental glomerulosclerosis (FSGS) recurrence after kidney transplantation is a leading cause of allograft failure and remains difficult to treat. Standard therapies, including plasma exchange (PEX) and rituximab, are often ineffective and poorly tolerated. Growing evidence implicates immune-mediated circulating factors, such as IgG and IgM autoantibodies, in disease pathogenesis. Given the central role of memory B cells and plasma cells in antibody production, we tested the safety/efficacy profile of a combined B-cell and plasma cell–depleting approach with rituximab and daratumumab in patients with posttransplant FSGS recurrence.
Methods
This is a retrospective analysis of a multicenter, international cohort of sixteen patients (median age 37 y) with biopsy-proven FSGS recurrence posttransplant who received anti-CD20 plus anti-CD38 monoclonal antibodies or anti-CD38 alone. The majority of patients were resistant to common therapies, including rituximab and PEX.
Results
The treatment achieved complete or partial remission in 5 and 11 patients, respectively. Five experienced proteinuria relapse, and 4 responded to repeated daratumumab alone. At the last follow-up (median 11 [2–18] mo), 13 patients are still in remission and PEX was discontinued in all but 3 cases. Overall, kidney function improved after treatment, and no severe acute or chronic adverse events were reported. Serological analysis revealed a significant decline in IgM, but not in IgG, after treatment.
Conclusions
Despite the retrospective, nonrandomized design, the temporal association between treatment and remission supports an effect of anti-CD38 monoclonal antibody alone or in combination with anti-CD20. Treatment is safe and may confer enhanced efficacy over standard approaches. Prospective, mechanistic studies are warranted to validate these findings and delineate the immunopathogenesis of FSGS recurrence.
Autor:innen und Institutionen
- Department of Medicine, Transplantation Research Center, Icahn School of Medicine at Mount Sinai, New York, NY.
- Nephrology Unit, University Hospital of Parma, Parma, Italy.
- Nephrology, Dialysis and Transplantation Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
- Division of Nephrology and Dialysis, Azienda Socio Sanitaria Territoriale (ASST) Spedali Civili de Brescia, Brescia, Italy.
- Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
- Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Zitieren
APA
Cravedi, P., Maggiore, U., Mortari, G., Alberici, F., La Manna, G., Goes, N., Bouvier, N., Comai, G., Mehr, A. P., Gentile, M., Palmisano, A., Gessaroli, E., Barbuto, S., Caridi, G., Bigatti, C., Magnasco, A., Bossini, N., Kajana, X., Spennacchio, A., …, & Angeletti, A. (2026). Combined Anti-CD20/Anti-CD38 Therapy in Posttransplant Focal Segmental Glomerulosclerosis Recurrence: A Retrospective, International, Multicenter Study. Transplantation Direct, 12(2), e1908. https://doi.org/10.1097/txd.0000000000001908
Vancouver
Cravedi P, Maggiore U, Mortari G, Alberici F, La Manna G, Goes N, et al. Combined Anti-CD20/Anti-CD38 Therapy in Posttransplant Focal Segmental Glomerulosclerosis Recurrence: A Retrospective, International, Multicenter Study. Transplantation Direct. 2026;12(2):e1908. doi:10.1097/txd.0000000000001908
BibTeX
@article{Cravedi2026,
author = {Cravedi, Paolo and Maggiore, Umberto and Mortari, Gabriele and Alberici, Federico and La Manna, Gaetano and Goes, Nelson and Bouvier, Nicolas and Comai, Giorgia and Mehr, Ali Poyan and Gentile, Micaela and Palmisano, Alessandra and Gessaroli, Elisa and Barbuto, Simona and Caridi, Gianluca and Bigatti, Carolina and Magnasco, Alberto and Bossini, Nicola and Kajana, Xhuliana and Spennacchio, Agnese and Gallon, Lorenzo and Ghiggeri, Gian Marco and Vincenti, Flavio and Hullekes, Frank E and Mehta, Rohan V and Riella, Leonardo V and Verrina, Enrico E and Angeletti, Andrea},
title = {Combined Anti-CD20/Anti-CD38 Therapy in Posttransplant Focal Segmental Glomerulosclerosis Recurrence: A Retrospective, International, Multicenter Study},
journal = {Transplantation Direct},
year = {2026},
volume = {12},
number = {2},
pages = {e1908},
doi = {10.1097/txd.0000000000001908}
}
EUVIMED